NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 226 citations · Michael Abern
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.
The New England journal of medicine · 2025 · 134 citations · Jiaoti Huang
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome.
The Journal of urology · 2022 · 268 citations · Quentin Clemens
International Alliance of Urolithiasis guideline on retrograde intrarenal surgery.
BJU international · 2023 · 93 citations · Glenn Preminger
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 248 citations · Christopher Hoimes
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
The Lancet. Oncology · 2021 · 402 citations · Leonard Gomella
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 259 citations · Michael Abern
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
Prostate cancer and prostatic diseases · 2024 · 126 citations · Judd Moul